These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38956524)

  • 1. Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.
    Weitzel J; Welsner M; Taube C; Ballmann M; Sutharsan S
    BMC Pulm Med; 2024 Jul; 24(1):307. PubMed ID: 38956524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    Patel N; Ansar M; Pham A; Thomsen K; McKinzie CJ; Polineni D; Esther CR; Brown RF
    Pediatr Pulmonol; 2024 Apr; 59(4):863-866. PubMed ID: 38179880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study.
    van der Meer R; Wilms EB; Eggermont MN; Paalvast HM; van Luin M; van Rossen RCJM; Heijerman HGM
    J Cyst Fibros; 2024 May; 23(3):549-553. PubMed ID: 38290918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review.
    Testa I; Indolfi G; Brugha R; Verkade HJ; Terlizzi V
    J Cyst Fibros; 2024 May; 23(3):554-560. PubMed ID: 38614868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis.
    McKinzie CJ; Kam CW; Jones MC; Gifford LB; Loughlin CE; Noah TL; Shenoy VK; Dellon EP
    Pediatr Pulmonol; 2024 Jun; 59(6):1795-1797. PubMed ID: 38517044
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor.
    Terlizzi V; Timpano S; Salvi M; Tosco A; Castaldo A; Fevola C; Leonetti G; Vitullo P; Sepe A; Badolato R; Salvatore D
    J Cyst Fibros; 2023 Nov; 22(6):1130-1132. PubMed ID: 37400299
    [No Abstract]   [Full Text] [Related]  

  • 8. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
    Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
    [No Abstract]   [Full Text] [Related]  

  • 10. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test.
    Mir-Ihara P; De Las Vecillas L; Heredia R; Fiandor A; González-Muñoz M; Zamarrón E; Prados C; Cabañas R
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):211-213. PubMed ID: 37966860
    [No Abstract]   [Full Text] [Related]  

  • 12. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
    Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
    Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
    [No Abstract]   [Full Text] [Related]  

  • 13. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational study.
    Blardone C; Gambazza S; Mariani A; Galgani R; Brivio A; Nobili RM; Rizza C; Tutino AL; Gramegna A; Daccò V; Contarini M; Blasi F; Laquintana D
    Ther Adv Respir Dis; 2024; 18():17534666241235054. PubMed ID: 38554035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant.
    Young D; Bartlett LE; Guimbellot J; Milinic T; Burdis N; Gill ER; Lease ED; Goss CH; Kapnadak SG; Ramos KJ
    J Cyst Fibros; 2024 May; 23(3):545-548. PubMed ID: 37798159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    James A; Li G; List R; Lonabaugh K; Smith AD; Barros A; Somerville L; Albon D
    Pediatr Pulmonol; 2024 Mar; 59(3):669-678. PubMed ID: 38088203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.
    Miller JE; Taylor-Cousar JL; Overdevest JB; Khatiwada A; Mace JC; Alt JA; Bodner TE; Chowdhury NI; DiMango EA; Eshaghian PH; Getz AE; Gudis DA; Han EJ; Hwang PH; Keating CL; Khanwalkar A; Kimple AJ; Lee JT; Li D; Markarian K; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Tervo JP; Turner GA; Wang MB; Saavedra MT; Beswick DM
    Int Forum Allergy Rhinol; 2024 Jun; 14(6):1079-1087. PubMed ID: 38145393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.
    Wiesel V; Aviram M; Mei-Zahav M; Dotan M; Prais D; Cohen-Cymberknoh M; Gur M; Bar-Yoseph R; Livnat G; Goldbart A; Hazan G; Hazan I; Golan-Tripto I
    J Cyst Fibros; 2024 Jan; 23(1):41-49. PubMed ID: 37173154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence and evolution of
    Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
    mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.